Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
Eli Lilly and Company
Cantargia AB
ImmunityBio, Inc.
Nektar Therapeutics
Incyte Corporation
Pfizer
Bayer
Eli Lilly and Company
AstraZeneca
Eli Lilly and Company
Eli Lilly and Company
Nanjing Luye Sike Pharmaceutical Co., Ltd.
Merck KGaA, Darmstadt, Germany
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Academy Military Medical Science, China
Eli Lilly and Company